6月5日，药捷安康-B盘中下跌5.41%，报32.14港元，成交额7285.01万港元。
消息面上，公司近日在ASCO大会以壁报形式公布了核心产品替恩戈替尼单药治疗既往FGFR抑制剂经治的晚期胆管癌患者关键II期临床数据，截至数据截止日共50例患者入组。生物科技板块整体偏弱，康方生物跌5.23%、百济神州跌3.04%、三生制药跌2.94%。此外，公司此前已获纳入香港交易所科技100指数，将于6月15日起生效。
药捷安康是一家专注于肿瘤、炎症及心脏代谢疾病小分子创新疗法的生物制药公司，核心产品替恩戈替尼为处于注册临床阶段的MTK抑制剂。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.